The National Epirubicin Adjuvant Trial (NEAT) was conducted in the Nation of England, while a very similar trial, BR9601, was conducted in Scotland. Both show that this agent reduces rates of death or recurrence when given for early breast cancer before the standard cocktail of cyclophosphamide, methotrexate and fluouracil. […]
NEJM 2 Nov 2006
